Potential Antisense Oligonucleotide Therapies for Neurodegenerative Diseases

Concepts in Gene Therapy

Volumn , Issue , 2020, Pages 141-167

  Grifman, Mirta ^a   Lev Lehman, Efrat ^a   Ginzberg, Dalia ^a   Eckstein, Fritz ^b   Zakut, Haim ^c   Soreq, Hermona ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85134274629     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1515/9783110808636-010     Document Type: Chapter

References (84)

1. Wagner, R. W. (1994). Gene inhibition using antisense oligodeoxynucleotides. Nature 372, 333-335.
2. Strauss, M. (1996). Antisense Molecules and Ribozymes: Medical Applications. Antisense Technology (in press).
3. McCarthy, M. M., Masters, D. B., Rimvall, K., Schwartz-Giblin, S., and Pfaff, D. W. (1994). Intracerebral administration of antisense deoxynucleotides to GAD65 and GAD67 mRNAs modulate reproductive behavior in the female rat. Brain Res. 636, 209-220.
4. Skutella, T., Probst, J. C., Jirikowski, G. F., Holsboer, F., and Spanagel, R. (1994). Ventral tegmental area (VTA) injection of tyrosine hydroxylase phosphorothioate antisense oligonucleotide suppresses operant behavior in rats. Neurosci. Lett. 167, 55-58.
5. Sakai, R. R., He, P. F., Yang, L. Y., Ma, Y. F. Guo, J. J., Reilly, C. N., and Fluharty, S. J. (1994). Intracerebroventicular administration of ATI receptor antisense oligonucleotides inhibits the behavioral actions of angiotensin II. J. Neurochem. 62, 2053-2056.
6. Maurizot, J. C., Brahms, J., and Eckstein, F. (1969). Forces involved in the conformational stability of nucleic acids. Nature 222, 559-561.
7. Halford, M. H. and Jones, A. S. (1968). Synthetic analogues of polynucleotides. Nature 217, 638-640.
8. Pitha, P. M., Teich, N. M., Lowy, D. R., and Pitha, J. (1973). Inhibition of murine leukemia virus replication by poly (vinyluracil) and poly (vinyladenine). Proc. Natl. Acad. Sci. USA 70, 1204-1208.
9. De Clercq, E., Eckstein, F., and Merigan, T.C. (1969). Interferon induction increased through chemical modification of a synthetic polyribonucleotide. Science 165, 1137-1139.
10. Zamecnik, P. C., Goodchild, J., Taguchi, Y., and Sarin P. S. (1986). Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA. Proc. Natl. Acad. Sci. USA 83, 4143-4146.
11. Matsukura, M., Shinozuka, K., Zon, G., Mitsuya, R. M., Cohen, J. S., and Broder S. (1987). Phosphorothioate analogs of oligodeoxynucleotide inhibitors of replication and effects on human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 84, 7706-7710.
12. Agrawal, S., Goodchild, J. Civeira, M. P. Thornton, A. H., Sarin, P. S., and Zamecnik P. C. (1988). Oligodeoxphosphoroamidates and phosphorothioates as inhibitors of human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 85, 7079-7083.
13. Stein, C. A. and Cheng, Y. C. (1993). Antisense oligonucleotides as therapeutic agents - Is the bullet really magical? Science 261, 1004-1012.
14. Eckstein, F. (1966). Nucleoside phosphorothioates. J. Am. Chem. Soc. 88, 4292-4294.
15. Eckstein, F. (1985). Nucleoside phosphorothioates. Annu. Rev. Biochem. 54, 367-402.
16. Eckstein, F. and Gish, G. (1989). Phosphothioates in molecular biology. Trends Biochem. Sci. 14, 97-100.
17. De Clercq, E., Eckstein, F., Sternbach, H., and Merigan, T.C. (1970). The antiviral activity of thiophosphate-substituted polyribonucleotides in vitro and in vivo. Virology 42, 421-428.
18. Zamecnik, P. C. and Stephenson, M. L. (1978). Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA 75, 280-284.
19. Hewick, R. M., Hunkapiller, M. W., Hood, L. E., and Dreyer, W.J. (1981). A gas-liquid solid phase peptide and protein sequenator. J. Biol. Chem. 256, 7990-7997.
20. Caruthers, M. H. (1985). Gene synthesis machines: DNA chemistry and its uses. Science 230, 281-285.
21. Alvarado-Urbina, G., Sathe, B. M., Liu, W.-C., Gillen, M. F., Duck, P. D., Bender, R., and Ogilvie, K. K. (1981). Automated synthesis of gene fragments. Science 214, 270-274.
22. Fakler, B., Herlitze, S., Amthor, B., Zenner, H. P., and Ruppersberg, J. P. (1994). Short antisense oligonucleotide-mediated inhibition is strongly dependent on oligo length and concentration but almost independent of location of the target sequence. J. Biol. Chem. 269, 16187-16194.
23. Bennett, C. F., Condon, T. P., Grimm, S., Chan, H., and Chiang, M. V. (1994). Inhibition of endothelial cell adhesion molecule expression with antisense oligonucleotides. J. Immunol. 152, 3530-3540.
24. Sarmiento, U. M., Perez, J. R., Becker, J. M., and Narayan, R. (1994). In vivo toxicological effects of rel A antisense phosphorothioates in CD-I mice. Antisense Res. Develop. 4, 99-107.
25. Ehrlich, G., Patinkin, D., Ginzberg, D., Zakut, H., Eckstein, F., and Soreq, H. (1994). Use of partially phosphorothioated “Antisense” oligodeoxynucleotides for sequence-dependent modulation of hematopoiesis. Antisense Res. Develop. 4, 173-183.
26. Stein, C. A. and Narayanan, R. (1994). Antisense oligodeoxynucleotides. Curr. Opin. Oncol. 6, 587-594.
27. Stein, C. A. and Krieg, A. M. (1995). Problems of interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res. Develop. 4, 67-69.
28. Morrison, P. F., Laske, D. W., Bobo, H., Oldfield, E. H., Dedrick, R. L. (1994). High-flow microinfusion: tissue penetration and pharmacodynamics. Am. J. Physiol. 266, R292-305.
29. Boado, R. J. and Pardridge, W. M. (1992). Complete protection of antisense oligonucleotides against serum nuclease degradation by an avidin-biotin system. Bioconjug. Chem. 3, 519-523.
30. Juliano, R. L. and Akhtar, S. (1992). Liposomes as a drug delivery system for antisense oligonucleotides. Antisense Res. Develop 2, 165-176.
31. Pardridge, W. M. (1992). Recent development in peptide drug delivery to the brain. Pharmacol. Toxicol. 71, 3-10.
32. Desjardins, J., Mata, J., Brown, T., Graham, D., Zon, G., and Iversen, P. (1995). Cholesterylconjugated phosphorothioate oligodeoxynucleotides modulate CYP2B1 expression in vivo. J. Drug Target 2, 477-85.
33. Pardridge, W. M. (1994). Vector-mediated delivery of a polyamide (“peptide”) nucleic acid analogue through the blood-brain barrier in vivo. Trends Biotechnol. 12, 239-245.
34. Pardridge, W. M., Boado, R. J., and Kang, Y. S. (1995). Vector-mediated delivery of a polyamide (“peptide”) nucelic acid analogue through the blood-brain barrier in vivo. Proc. Natl. Acad. Sci., USA. 92, 5592-5596.
35. Hooper, M. L., Chiasson, B. J., and Robertson, H. A. (1994). Infusion into the brain of an antisense oligonucleotide to the immediate-early gene c-fos suppresses production of fos and produces a behavioral effect. Neurosci. 63, 917-924.
36. Moller, C., Bing, O., and Heilig, M. (1994). c-fos expression in the amygdala: in vivo antisense modulation and role in anxiety. Cell. Molec. Neurobiol. 14, 415-423.
37. Landgraf, R., Gerstberger, R., Montkowski, A., Probst, J.C., Wotjak, C.T., Holsboer, F., and Engelmann, M. (1995). VI vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities and anxiety-related behavior in rats. J. Neurosci. 15, 4250-4258.
38. Bourson, A., Borroni, E., Austin, R. H., Monsma, F. J. Jr; and Sleight, A. J. (1995). Determination of the role of the 5-ht6 receptor in the rat brain: a study using antisense oligonucleotides. J. Pharmacol. Exp. Ther. 274, 173-180.
39. Akabayashi, A., Wahlestedt, C., Alexander, J. T., and Leibowitz, S. F. (1994). Specific inhibition of endogenous neuropeptide Y synthesis in arcuate nucleus by antisense oligonucleotides suppresses feeding behavior and insulin secretion. Molec. Brain Res. 21, 55-61.
40. Spampinato, S., Canossa, M., Carboni, L., Campana, G., Leanza, G., and Ferri, S. (1994). Inhibition of proopiomelanocortin expression by an oligodeoxynucleotide complementary to beta -endorphin mRNA. Proc. Natl. Acad. Sci. USA. 91, 8072-8076.
41. Silvia, C. P., King, G. R., Lee, T. H., Xue, Z. Y., Caron, M. G., and Ellinwood, E. H. (1994). Intranigral administration of D2 dopamine receptor antisense oligodeoxynucleotides establishes a role for nigrostriatal D2 autoreceptors in the motor actions of cocaine. Molec. Pharmacol. 46, 51-57.
42. Dragunow M., Lawlor, P., Chiasson, B., and Robertson, H. (1993). c-fos antisense generates apomorphine and amphetamine-induced rotation. Neuroreport 5, 305-306.
43. Sommer, N., Melms, A., Weller, M., and Dichgans, J. (1993). Ocular myasthenia gravis. A critical review of clinical and pathological aspects. Doc. Opthalmol. 84, 309-333.
44. Zhou, L. W., Zhang, S. P., Quin, Z. H., and Weiss, B. (1994). In vivo administration of an oligodeoxynucleotide antisense to the D2 dopamine receptor messenger RNA inhibits D2 dopamine receptor-mediated behavior and the expression of D2 dopamine receptors in mouse striatum. J. Pharmacol. Exp. Ther. 268, 1015-1023.
45. Katz, B. and Miledi, R. (1973). The binding of acetylcholine to receptors and its removal from the synaptic cleft. J. Physiol. Lond. 231, 549-574.
46. Coyle, J. T., Price, D. L., and DeLong, M. R. (1983). Alzheimer’s disease: a disorder of cortical cholinergic innervation. Science 219, 1184-1189.
47. Katzman, R. (1986). Alzheimer’s disease. New Eng. J. Med. 314, 964-973.
48. Davis, R. E., Emmerling, M. R., Jaén, J. C., Moos, W. H., and Spiegel, K. (1993). Therapeutic intervention in dementia. Crit. Rev. Neurobiol. 7, 41-83.
49. Kadar, T., Silbermann, M., Weissman, B. A., and Levy, A. (1990). Age-related changes in the cholinergic components within the central nervous system II. Working memory impairement and its relation to hippocampal muscarinic receptors. Mech. Aging Develop. 55, 139-149.
50. Beeri, R. Andres, C., Lev-Lehman, E., Timberg, R., Huberman, T., Shani, M., and Soreq, H. (1995). Transgenic expression of human acetylcholinesterase induces progressive cognitive deterioration in mice. Curr. Biol. 5, 1063-1071.
51. Crimson, M. L. (1994). Tacrine: first drug approved for Alzheimer’s disease. Ann. Pharmacother. 28, 744-751.
52. Wagstaff, A. J. and McTavish, Y. (1994). Tacrine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer’s disease. Drugs Aging 4, 510-540.
53. Knapp, M. J., K, D. S., Solomon, P. R., Pendlebury, W. W., Davis, C. S., and Gracon, S. I. (1994). A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease. JAMA 271, 985-991.
54. Loewenstein-Lichtenstein, Y., Schwarz, M., Glick, D., Norgaard-Pedersen, B., Zakut, H., and Soreq, H. (1995). Genetic predisposition to adverse consequences of anticholinesterases in ‘atypical’ BCHE carriers. Nature Med. 1, 1082-1085.
55. Esmaeli-Azad, B., McCarty, J. H., and Feinstein, S. C. (1994). Sense and antisense transfection analysis of tau function: tau influences net microtubule assembly, neurite outgrowth and neuritic stability. J. Cell Sci. 107, 869-879.
56. Majocha, R. E., Agrawal, S., Tang, J. Y., Humke, E. W., and Marotta, C. A. (1994). Modulation of the PC 12 cell response to nerve growth factor by antisense oligonucleotide to amyloid precursor protein. Cell. Mol. Neurobiol. 14, 425-437.
57. Karpel, R., Sternfeld, M., Ginzberg, D., Guhl, E., Graessman, A., and Soreq H. (1996). Overexpression of alternative human acetylcholinesterase forms modulates extensions in cultured glioma cells. J. Neurochem. 66, 114-123.
58. Seidman, S., Sternfeld, M., Ben Aziz-Aloya, R., Timberg, R., Kaufer, D., and Soreq, H. (1995). Synaptic versus epidermal accumulation of human acetylcholinesterase is encoded by alternative 3'-terminal exons. Molec. Cell Biol. 14, 459-473.
59. Andres, C., Beeri, R., Huberman, T., Shani, M., and Soreq, H. (1996). Cholinergic drug resistance and impaired spatial learning in transgenic mice overexpressing human brain acetylcholinesterase. K. Loffelholz, Ed. Prog. Brain. Res. 109, pp. 265-272.
60. Soreq, H., Patinkin, D., Lev-Lehman, E., Ginzberg, D., Grifman, M., Eckstein, F., and Zakut, H. (1994). Antisense oligonucleotide inhibition of acetylcholinesterase gene expression induces progenitor cell expansion and suppresses hematopoietic apoptosis ex vivo. Proc. Natl. Acad. Sci USA. 91, 7907-7911.
61. Lev-Lehman, E., Ginzberg, D., Hornreich, G., Ehrlich, G. Meshorer, A., Eckstein, F., Soreq, H., and Zakut, H. (1994). Antisense inhibition of acetylcholinesterase gene expression causes transient hematopoietic alterations in vivo. Gene Therapy 1, 127-135.
62. Soreq, H. and Zakut, H. (1993). Human Cholinesterases and Anticholinesterases. San Diego Academic Press.
63. Massoulie, J., Pezzementi, L., Bon, S., Krejci, E., and Vallette, F. M. (1994). Molecular and cellular biology of the cholinesterases. Prog. Neurobiol. 41, 31-91.
64. Schwarz, M., Glick, D., Loewenstein, Y., and Soreq, H. (1995). Engineering of human cholinesterases explains and predicts diverse consequences of administration of various drugs and poisons. Pharmac. Ther. 67, 283-322.
65. Layer, P. G., Weikert, T., and Willbold, E. (1992). Chicken retinospheroids as developmental and pharmacological in vitro models: acetylcholinesterase is regulated by its own and by butyrylcholinesterase activity. Cell Tissue-Res. 268, 409-418.
66. Catalono, S. M., Robertson, R. T., and Killackey, H. P. (1991). Early ingrowth of thalamocortical afferents to the neocortex of the prenatal Rat. Proc. Natl. Acad. Sci. USA 88, 299-3003.
67. Shapira, M., Seidman, S., Sternfeld, M., Timberg, R., Kaufer, D., Patrick, J. W., and Soreq, H. (1994). Transgenic engineering of neuromuscular junctions in Xenopus laevis embryos transiently overexpressing key cholinergic proteins. Proc. Natl. Acad. Sci. USA 91, 9072-9076.
68. Layer, P. G., Weikert, T., and Alber, R. (1993). Cholinesterases regulate neurite growth of chick nerve cells in vitro by means of a non-enzymatic mechanism. Cell Tissue Res. 273, 219-226.
69. Small, D. H., Reed, G., Whitefield, B., and Nurcombe, V. (1995). Cholinergic regulation of neurite outgrowth from isolated chick sympathetic neurons in culture. J. Neurosci. 15, 144-151.
70. Karpel, R., Ben Aziz-Aloya R., Sternfeld, M., Ehrlich, G., Ginzberg, D., Tarroni, P., Clementi, E, Zakut, H., and Soreq, H. (1994). Expression of three alternative acetylcholinesterase messenger RNAs in human tumor cell lines of different tissue origins. Exp. Cell Res. 210, 268-277.
71. Yu, C., Brussaard, A. B., Yang, X., Listerud, M., and Role L.W. (1993). Uptake of antisense oligonucleotides and functional block of acetylcholine receptor subunit expression in primary embryonic neurons. Dev. Genet. 14, 296-304.
72. Grifman, M., Ginzburg, D., and Soreq, H. (1995). Impairment of neurite extension and apoptosisdependent DNA fragmentation in primary neuronal cell cultures administered with an ACHE antisense oligonucleotide. J. Neurochem. 65 (Suppl.), 82.
73. Weiss, S., Pin, J. P., Sebben, M., Kemp, D.E., Sladeczek, F., Gabrion, J., and Bockaert, J. (1986). Synaptogenesis of cultured striatal neurons in serum free medium: a morphological and biochemical study. Proc. Natl. Acad. Sci. USA 83, 2238-2242.
74. Zimmermann, H., Heilbronn, A., Braun, N., Carstensen, C., Kegel, B., and Maienschein, V. (1995). Extracellular metabolism of nucleotides in the nervous system. J. Neurochem. 65 (Suppl.), 210.
75. Brown, L. M., Blair, A., Gibson, R., Everett, G. D., Cantor, K. P., Shuman, L. M., Burmeister, L. F. Van Lier, S. F., and Dick, F. (1990). Pesticide exposures and other agricultural risk factors for leukemia among men in Iowa and Minnesota. Cancer Res. 50, 6585-6591.
76. Lapidot-Lifson, Y., Prody, C. A., Ginzberg, D., Meytes, D., Zakut, H., and Soreq, H. (1989). Co amplification of human acetylcholinesterase and butyrylcholinesterase genes in blood cells: Correlation with various leukemias and abnormal megakaryocytopoiesis. Proc. Natl. Acad. Sci. USA 86, 4715-4719.
77. Zakut, H., Lapidot-Lifson, Y., Beeri, R., Ballin A., and Soreq, H. (1992). In vivo gene amplification in non-cancerous cells: Cholinesterase genes and oncogenes amplify in thrombocytopenia associated with lupus erythematosus. Mut. Res. 276, 275-284.
78. Patinkin, D., Seidman, S., Eckstein, F., Benseier, F., Zakut, H., and Soreq, H. (1990). Manipulations of Cholinesterase gene expression modulate murine megakaryocytopoiesis in vitro. Molec. Cell Biol. 10, 6046-6050.
79. Wagner, R. (1995). Toward a broad-based antisense technology. Antisense Res. Develop. 5, 113-144.
80. Soreq, H., Lev-Lehman, E., Patinkin, D., Grifman, M., Ehrlich, G., Ginzberg, D., Eckstein, F., and Zakut, H. (1995). Antisense oligonucleotides suppressing expression of Cholinesterase genes modulate hematopoiesis in vivo and ex vivo. In: Enzymes of the Cholinesterase Family, D. M. Quinn, A. S. Balasubramanian, B. P. Doctor and P.Taylor, eds. New York: Plenum Press, 1-6.
81. Patinkin, D., Lev-Lehman, E., Zakut, H., Eckstein F., and Soreq, H. (1994). Antisense inhibition of butyrylcholinesterase gene expression predicts adverse hematopoietic consequences to Cholinesterase inhibitors. Cell. Molec. Neurobiol. 14, 459-473.
82. Winker, M.A. (1994). Tacrine for Alzheimer’s disease, which patent, what dose? JAMA 271, 1023-1024.
83. Gavrieli, Y., Sherman, Y., and Ben-Sasson S. (1992). Identification of programmed ell deeath in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 119, 493-501.
84. Harik, S. I. and Kalaria, R. N. (1991). Blood-brain barrier abnormalities in Alzheimer’s disease. Ann. N.Y. Acad. Sci. 640, 47-52.